Entest BioMedical Files Patent Application for Selective Targeting of Stem Cells to Lung Using Photoceutical Devices

New Technology to Increase Efficacy of Adult Stem Cells in COPD Treatment

• Press Release
• Source: Entest BioMedical Inc.
• On 5:00 am EST, Wednesday November 4, 2009

SAN DIEGO--(BUSINESS WIRE)--Entest BioMedical (OTCBB: ENTB - News) announced today it has filed a second patent application in the area of Chronic Obstructive Pulmonary Disease (COPD). This new patent application builds upon the Company’s previously filed COPD patent application and involves the use of photoceutical devices to target stem cells toward areas impacted by COPD in the lungs.

Related Quotes

Symbol	Price	Change
BMSN.OB	0.08	+0.01

{"s" : "bmsn.ob,entb.ob","k" : "c10,l10,p20,t10","o" : "","j" : ""}

Steve Josephs, PhD, a Scientific Advisor to the Company stated “that by using photoceutical devices in treating COPD, it is believed stem cells can be focused on areas of the lungs where there is damage. Furthermore, being able to target specific areas and draw stem cells to those areas should produce greater efficacy in patient treatment outcomes. ”

David Koos, Chairman and CEO of Entest stated, “This new patent application we filed covers methods of enhancing our previously disclosed adult stem cell technologies in the treatment of COPD. It is our belief the use of photoceuticals devices coupled with adult stem cell therapy is a treatment model completely new and unique to addressing this terrible disease.”

Entest’s treatment approach for COPD is based on the development of easy-to-implement therapies involving the use of stem cells, and other cells found in the fat tissue of the patient. By incorporating photoceutical devices currently in use for other clinical treatments, this invention discloses methods of increasing the rate of cell homing, retention, and growth factor production in the lung.

About Entest BioMedical Inc.:

Entest BioMedical Inc. (OTCBB: ENTB - News) is a majority owned subsidiary of Bio-Matrix Scientific Group Inc (OTCBB: BMSN - News). The Company is involved with the development of stem cell therapy treatments for Chronic Obstructive Pulmonary Disease (COPD), immuno-cancer therapies, testing procedures for diabetes, stem cell research applications for diabetes and other illnesses. The Company also is involved with medical device development (including stem cell extraction instrumentation).

Disclaimer

This news release may contain forward-looking statements. Forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified. Future events and actual results could differ materially from those set forth in, contemplated by, or underlying the forward-looking statements. The risks and uncertainties to which forward-looking statements are subject include, but are not limited to, the effect of government regulation, competition and other material risks.

Entest BioMedical Inc.
David R. Koos, Chairman & CEO
619-702-1404 Direct
619-330-2328 Fax
info@EntestBio.com
www.EntestBio.com